HomePress-release

Redding, California - September 25, 2024

Regenerative Medicine Market to be Worth $37.27 Billion by 2031

Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User - Global Forecast to 2031

Meticulous Research^®—a leading global market research company, published a research report titled ‘Regenerative Medicine Market - Global Opportunity Analysis and Industry Forecasts to 2031.’ According to this latest publication from Meticulous Research^®, the regenerative medicine market is projected to reach $37.27 billion by 2031 at a CAGR of 21.5% from 2024 to 2031.

The growth of the regenerative medicine market is driven by regulatory approvals for new regenerative medicines, advancements in the field of regenerative medicine, the rising burden of chronic diseases, growing funding for research and development on regenerative medicine, and the expanding applications of regenerative medicines in newer therapeutic areas.

Furthermore, the rising adoption of personalized medicines, the growing number of organ transplants, and the strong product pipeline for regenerative medicines are expected to generate market growth opportunities.

Key Players

The key players operating in the regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.).

Regenerative Medicine Market: Future Outlook

The regenerative medicine market is segmented by Product, Application, and End User. The report also evaluates industry competitors and analyzes the regenerative medicine market at the regional and country levels.

Among the products studied in this report, in 2024, the cell therapy segment is anticipated to dominate the regenerative medicine market with a share of 51.2%. Increasing public & private funding for stem cell therapy development, government efforts to streamline approval procedures, and collaborations among key players to advance stem cell therapy for various applications are factors contributing to the segment’s dominant position in the regenerative medicine market.

Stem cell therapy is a minimally invasive procedure that reduces the need for extensive surgeries and lengthy recovery periods. Since it utilizes the patient's body cells, it minimizes the risk of side effects and provides personalized treatment, making it a preferred option over other therapies.

Among the applications studied in this report, in 2024, the musculoskeletal segment is expected to account for the largest share of 31.9% of the regenerative medicine market. The rising burden of musculoskeletal conditions, the benefits offered by regenerative medicine therapies in pain management, and the robust product pipeline of regenerative medicines for musculoskeletal conditions are factors contributing to the segment’s dominant position in the regenerative medicine market.

According to the World Health Organization (WHO), in 2021, approximately 1.71 billion individuals worldwide were affected by musculoskeletal conditions. The WHO has projected a rise in disabilities associated with these conditions in the coming decades.

Among the end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the larger share of the regenerative medicine market. The proliferation of public and private hospitals, the increasing prevalence of chronic diseases leading to higher hospital admissions, and the rising availability of regenerative medicine treatments in hospital settings are factors contributing to the segment’s dominant position in the regenerative medicine market.

Among the regions studied in this report, in 2024, North America is anticipated to dominate the regenerative medicine market, with a share of 41.8%. High healthcare expenditure, the presence of key market players actively engaged in the development of regenerative medicines, and high investments by both public and private entities are factors contributing to the segment’s dominant position in the regenerative medicine market. According to the Alliance for Regenerative Medicine (U.S.), an international organization dedicated to advancing regenerative medicine, investments in regenerative medicine in North America reached $8.3 billion in the fourth quarter of 2023, an increase from $1.1 billion in the third quarter of the same year.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5864

Key Questions Answered in the Report:

Which are the high-growth market segments in terms of product, application, end user, and region/country?
What was the historical market size for regenerative medicines globally?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, opportunities, challenges, and trends in the regenerative medicine market?
Who are the major players in the regenerative medicine market?
What is the competitive landscape like, and who are the market leaders in the regenerative medicine market?
What are the recent developments in the regenerative medicine market?
What are the growth strategies adopted by major players in the regenerative medicine market?
What are the geographic trends, and which are the high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & WastewaterTechnologies

Miscellaneous / Others

Redding, California - September 25, 2024

Regenerative Medicine Market to be Worth $37.27 Billion by 2031

Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User - Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies